Patents by Inventor Shi-He Liu

Shi-He Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Smart Exosomes for Active PDAC Targeting and Evading Mononuclear Phagocytotic System
    Publication number: 20240398974
    Abstract: Exosomes that express peptides in CD9 proteins, and smart exosomes that co-express two peptides incorporated into CD9 proteins to home delivery of the exosomes to a desired target and evade phagocytosis by macrophages, are described.
    Type: Application
    Filed: August 13, 2024
    Publication date: December 5, 2024
    Applicant: The University of Toledo
    Inventors: Shi-He Liu, Francis Charles Brunicardi
  • Automatic Fraction Collector
    Publication number: 20240319053
    Abstract: An automatic fraction collector, methods of using the same, and systems including the same are described. The automatic fraction collector includes a sensor assembly able to detect liquid drops passing therethrough with light, where the sensor assembly is in the fluid flow path between a column and the point of collection of the liquid drops.
    Type: Application
    Filed: March 15, 2024
    Publication date: September 26, 2024
    Applicant: The University of Toledo
    Inventor: Shi-He Liu
  • Smart exosomes for active PDAC targeting and evading mononuclear phagocytotic system
    Patent number: 12090213
    Abstract: Exosomes that express peptides in CD9 proteins, and smart exosomes that co-express two peptides incorporated into CD9 proteins to home delivery of the exosomes to a desired target and evade phagocytosis by macrophages, are described. Provided are exosomes useful for delivering drugs to desired targets. The exosomes comprise drugs, such as chemotherapeutic drugs, encapsulated in their core. The targets include pancreatic cancer cells.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: September 17, 2024
    Assignee: The University of Toledo
    Inventors: Shi-He Liu, Francis Charles Brunicardi
  • C PRIME AGENTS FOR TREATING METABOLIC DISORDERS
    Publication number: 20240150279
    Abstract: Stably consolidated compounds assembled from a statin and a metformin analog, and metabolically labile dual prodrugs assembled from the same, methods of making both, and methods of using them to treat metabolic diseases such as cancers are described.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 9, 2024
    Applicant: The University of Toledo
    Inventors: Paul Erhardt, Shi-He Liu, Francis Charles Brunicardi, Divya Andy
  • SMART EXOSOMES FOR ACTIVE PDAC TARGETING AND EVADING MONONUCLEAR PHAGOCYTOTIC SYSTEM
    Publication number: 20240042055
    Abstract: Exosomes that express peptides in CD9 proteins, and smart exosomes that co-express two peptides incorporated into CD9 proteins to home delivery of the exosomes to a desired target and evade phagocytosis by macrophages, are described. Provided are exosomes useful for delivering drugs to desired targets. The exosomes comprise drugs, such as chemotherapeutic drugs, encapsulated in their core. The targets include pancreatic cancer cells.
    Type: Application
    Filed: March 17, 2022
    Publication date: February 8, 2024
    Applicant: The University of Toledo
    Inventors: Shi-He Liu, Francis Charles Brunicardi
  • TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY
    Publication number: 20220151976
    Abstract: Described herein are compositions, formulations, and methods useful for sensitizing cancer cells to chemotherapeutic agents, for inhibiting expression or translation of oncogenic proteins, for inhibiting eIF4A, for inhibiting c-MYC, for reducing sternness of breast cancer cells, for treating breast cancer, for overcoming drug resistance of drug-resistant cancer cells, and for reducing tumor cell viability, involving one or more inhibitors of eIF4A, LASP1, CXCR4, CXCL8, CXCL12, ROCK1, BIRC5, MDM2, CCND1, and c-MYC.
    Type: Application
    Filed: February 17, 2020
    Publication date: May 19, 2022
    Applicant: The University of Toledo
    Inventors: Dayanidhi Raman, Cory M. Howard, John Nemunaitis, Francis Charles Brunicardi, Shi-He Liu, Amit K. Tiwari
  • Synthetic promoters for high throughput screening and gene modulation
    Patent number: 11060087
    Abstract: The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed from the endogenous promoter of BIRC5 and LAMC2. In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Francis C. Brunicardi, Shi-He Liu
  • SYNTHETIC PROMOTERS FOR HIGH THROUGHPUT SCREENING AND GENE MODULATION
    Publication number: 20180009864
    Abstract: The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed from the endogenous promoter of BIRC5 and LAMC2. In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide.
    Type: Application
    Filed: June 14, 2017
    Publication date: January 11, 2018
    Applicant: The Regents of the University of California
    Inventors: Francis C. Brunicardi, Shi-He Liu
  • Synthetic promoter for modulating gene expression
    Patent number: 9644205
    Abstract: The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed using selected PDX-1 activation sites such as those observed in the human insulin promoter (HIP). In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: May 9, 2017
    Assignees: The Regents of the University of California, Baylor College of Medicine
    Inventors: Francis C. Brunicardi, Shi-He Liu
  • SYNTHETIC PROMOTER FOR MODULATING GENE EXPRESSION
    Publication number: 20150218555
    Abstract: The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed using selected PDX-1 activation sites such as those observed in the human insulin promoter (HIP). In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide.
    Type: Application
    Filed: April 24, 2013
    Publication date: August 6, 2015
    Inventors: Francis C. Brunicardi, Shi-He Liu